Melanoma

**Observational**
- IRB#17104
  DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Uveal Melanoma**
- IRB#16162
  A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

**Adjuvant Therapies**
- IRB#11848
  Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
- IRB#15661
  A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB#16883
  A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection
- IRB#16125
  A Phase 1b/2, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of SD-101 with Pembrolizumab in Patients With Metastatic Melanoma
- IRB#16198
  A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides
- IRB# 17666
  New study coming soon

**Stages 3 or 4, unresectable**
- IRB# 17480
  New study coming soon

**Stages 2B, 2C, or 3**
- IRB# 17666
  New study coming soon

**Non-Mutation Specific**
- IRB#15661
  A Phase 1b, Open-label, Dose-escalation and Expansion Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

**Mutation Specific**
- BRAF V600 Mutation

**Please refer to Phase I studies for more clinical trial opportunities**

http://www.ohsu.edu/research/rda.so/knight.php